Abstract
According to classical thinking about Parkinsons disease, loss of dopaminergic input from the substantia nigra pars compacta leads to overactivity and underactivity of the indirect and direct output pathways, respectively, in the basal ganglia. Administration of the dopamine precursor L-DOPA (l-3, 4-dihydroxyphenylalanine) is proposed to induce changes in the opposite directions. L-DOPA is the most used drug to treat Parkinsons disease symptoms. After repeated treatment with this compound, however, disabling secondary effects such as the abnormal involuntary movements usually appear. Nitric oxide is a free radical that can also acts as an atypical neurotransmitter and influences dopamine-mediated neurotransmission. In this paper we will briefly review the role of nitric oxide on motor control and in Parkinsons disease, particularly a possible role of nitric oxide in L-DOPA induced dyskinesia in rodents. Recent results show that nitric oxide synthase inhibition reduces L-DOPA-induced dyskinesia in rats and mice. The effect is dose-dependent, does not suffer tolerance nor interferes with L-DOPA positive motor effects. These preclinical findings suggest that nitric oxide is a promising therapeutic target for the reduction of L-DOPA-induced dyskinesia.
Keywords: 7-Nitroindazole, Motor behaviour, Nitric oxide synthase inhibitor, Dopamine, Mice, L-DOPA, Dyskinesia, Parkinson's disease, Abnormal involuntary movements
Current Pharmaceutical Design
Title: Role of Nitric Oxide in Motor Control: Implications for Parkinsons Disease Pathophysiology and Treatment
Volume: 17 Issue: 5
Author(s): Elaine Del-Bel, Fernando Eduardo Padovan-Neto, Rita Raisman-Vozari and Marcio Lazzarini
Affiliation:
Keywords: 7-Nitroindazole, Motor behaviour, Nitric oxide synthase inhibitor, Dopamine, Mice, L-DOPA, Dyskinesia, Parkinson's disease, Abnormal involuntary movements
Abstract: According to classical thinking about Parkinsons disease, loss of dopaminergic input from the substantia nigra pars compacta leads to overactivity and underactivity of the indirect and direct output pathways, respectively, in the basal ganglia. Administration of the dopamine precursor L-DOPA (l-3, 4-dihydroxyphenylalanine) is proposed to induce changes in the opposite directions. L-DOPA is the most used drug to treat Parkinsons disease symptoms. After repeated treatment with this compound, however, disabling secondary effects such as the abnormal involuntary movements usually appear. Nitric oxide is a free radical that can also acts as an atypical neurotransmitter and influences dopamine-mediated neurotransmission. In this paper we will briefly review the role of nitric oxide on motor control and in Parkinsons disease, particularly a possible role of nitric oxide in L-DOPA induced dyskinesia in rodents. Recent results show that nitric oxide synthase inhibition reduces L-DOPA-induced dyskinesia in rats and mice. The effect is dose-dependent, does not suffer tolerance nor interferes with L-DOPA positive motor effects. These preclinical findings suggest that nitric oxide is a promising therapeutic target for the reduction of L-DOPA-induced dyskinesia.
Export Options
About this article
Cite this article as:
Del-Bel Elaine, Eduardo Padovan-Neto Fernando, Raisman-Vozari Rita and Lazzarini Marcio, Role of Nitric Oxide in Motor Control: Implications for Parkinsons Disease Pathophysiology and Treatment, Current Pharmaceutical Design 2011; 17 (5) . https://dx.doi.org/10.2174/138161211795164176
DOI https://dx.doi.org/10.2174/138161211795164176 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?
Current Neuropharmacology Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets Issues in Rehabilitation of Cognitive Deficits in Schizophrenia: A Critical Review
Current Psychiatry Reviews The Effectiveness of Treatments for Cocaine Dependence in Schizophrenic Patients: A Systematic Review
Current Neuropharmacology Are Antipsychotics Useful in the Treatment of Anorexia Nervosa? A Review of the Literature
Current Psychopharmacology Inflammatory Process in Parkinsons Disease: Role for Cytokines
Current Pharmaceutical Design Effects of Exercise and Ferulic Acid on Alpha Synuclein and Neuroprotective Heat Shock Protein 70 in An Experimental Model of Parkinsonism Disease
CNS & Neurological Disorders - Drug Targets Prevalence, Severity and Characteristics of Tardive Dyskinesia Among Schizophrenia Patients in an Israeli Psychiatric Center
Current Psychopharmacology Gender Differences in Pharmacokinetics and Side Effects of Second Generation Antipsychotic Drugs
Current Neuropharmacology Revisiting the Medical Management of Parkinson’s Disease: Levodopa versus Dopamine Agonist
Current Neuropharmacology Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer’s and Parkinson’s Disease
Current Medicinal Chemistry Risperidone Rechallenge for Marked Liver Function Test Abnormalities in an Autistic Child
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Current Pharmaceutical Design Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases
Current Medicinal Chemistry Blockers of Voltage-Gated Sodium Channels for the Treatment of Central Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Current Therapeutic Options for Alzheimers Disease
Current Genomics New Trends in the Treatment of Schizophrenia
CNS & Neurological Disorders - Drug Targets Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Role of Dopamine Signaling in Drug Addiction
Current Topics in Medicinal Chemistry Halogen Dance Reaction and its Application in Organic Synthesis
Current Organic Chemistry